Centauri Therapeutics

7 articles with Centauri Therapeutics

• Centauri Therapeutics to Attend Scientific and Investor Conferences

  9/30/2019

  Centauri Therapeutics, an immunotherapy company active in oncology and infectious diseases, announces that it will attend the following scientific and investor conferences

• Centauri response by Dr Mike Westby, CEO of Centauri Therapeutics, to Dr Rick Bright, BARDA, Forbes article 10 May 19, “Building New Models To Support The Ailing Antibiotics Market”

  5/23/2019

  Centauri Therapeutics (“Centauri”) is an immunotherapy company active in oncology and infectious diseases.

• Centauri's AlphamerTM Platform highlighted at 4th Annual Advances in Immuno-Oncology Congress

  5/22/2019

  Centauri Therapeutics (“Centauri”), an immunotherapy company active in oncology and infectious diseases, announces that Mel Glossop, Head of Chemistry at Centauri, presented at the 4th Annual Advances in immune-Oncology Congress London, on 20 – 21 May.

• Centauri Therapeutics to present at 29th European Congress of Clinical Microbiology & Infectious Diseases

  4/10/2019

  Jennifer Schneider, PhD.  Vice President, Business Development at Centauri Therapeutics, will be presenting during the “Therapeutics pipeline corner” session, at 12.15pm CET on 14 April 2019.

• Centauri Therapeutics Receives Innovate UK Biomedical Catalyst Award

  9/11/2017

• Centauri Therapeutics Closes £2.5 Million Fundraising

  2/20/2017

• Centauri Therapeutics Extends Research Partnership With Peakdale Molecular Ltd.

  7/11/2016